Site search- 2023.5.12IRFinancial Results for the Fiscal Year ended March 31, 2023 [Japanese GAAP] (non-consolidated)（567KB）
- 2023.5.2IRBrightPath Biotherapeutics and Artisan Bio Announce Research and Licensing Agreement to Accelerate Development of BrightPath's Novel Allogeneic iPSC Derived Cell Therapy Platform across Multiple Indications（173KB）
- 2023.5.12IRFinancial Results for the Fiscal Year ended March 31, 2023 [Japanese GAAP] (non-consolidated)（567KB）
- 2023.5.2IRBrightPath Biotherapeutics and Artisan Bio Announce Research and Licensing Agreement to Accelerate Development of BrightPath's Novel Allogeneic iPSC Derived Cell Therapy Platform across Multiple Indications（173KB）